Relevant bibliographies by topics / Saxagliptin

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Saxagliptin'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Saxagliptin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Saxagliptin"

1

Shubrook, Jay, Randall Colucci, Aili Guo, and Frank Schwartz. "Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus." Clinical Medicine Insights: Endocrinology and Diabetes 4 (January 2011): CMED.S5114. http://dx.doi.org/10.4137/cmed.s5114.

Full text
Abstract:
The prevalence of type 2 diabetes mellitus is high and growing rapidly. Suboptimal glycemic control provides opportunities for new treatment options to improve the morbidity and mortality of this progressive disease. Saxagliptin, a selective DPP-4 inhibitor, increases endogenous incretin levels and incretin acitivty. In controlled clinical trials saxagliptin reduces both fasting and postprandial glucose and works in monotherapy and in combination with metformin, TZDs and sulfonylureas. Saxagliptin has a very favourable side effect profile and may have other beneficial non-glycemic effects. The
APA, Harvard, Vancouver, ISO, and other styles
2

Ayoub, Bassam M., Ramzia I. El-Bagary, and Ehab F. Elkady. "Spectrophotometric Methods Based on Charge Transfer ComplexationReactions for the Determination of Saxagliptin in Bulk and Pharmaceutical Preparation." International Journal of Biomedical Science 8, no. 3 (2012): 204–8. http://dx.doi.org/10.59566/ijbs.2012.8204.

Full text
Abstract:
Simple, accurate and precise spectrophotometric methods have been developed for the determination of saxagliptin in bulk and dosage forms.The proposed methods are based on the charge transfer complexes of saxagliptin with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) and7,7,8,8-tetracyanoquinodimethane (TCNQ). All the variables were studied to optimize the reactions' conditions. Beer's law was obeyed in the concentration ranges of 50-300 μg/ml and 10- 110 μg/ml with DDQ and TCNQ, respectively.The developed methods werevalidated and proved to be precise and accurate for the quality control of
APA, Harvard, Vancouver, ISO, and other styles
3

Kim, Ki-Young, Yeo-Jin Jeong, So-Young Park, et al. "Evaluation of the Drug-Induced Liver Injury Potential of Saxagliptin through Reactive Metabolite Identification in Rats." Pharmaceutics 16, no. 1 (2024): 106. http://dx.doi.org/10.3390/pharmaceutics16010106.

Full text
Abstract:
A liver injury was recently reported for saxagliptin, which is a dipeptidyl peptidase-4 (DPP-4) inhibitor. However, the underlying mechanisms of saxagliptin-induced liver injury remain unknown. This study aimed to evaluate whether saxagliptin, a potent and selective DPP-4 inhibitor that is globally used for treating type 2 diabetes mellitus, binds to the nucleophiles in vitro. Four DPP-4 inhibitors, including vildagliptin, were evaluated for comparison. Only saxagliptin and vildagliptin, which both contain a cyanopyrrolidine group, quickly reacted with L-cysteine to enzyme-independently produc
APA, Harvard, Vancouver, ISO, and other styles
4

Wu, Suyan, Haifei Pan, and Yingying Huang. "Pharmacokinetic interaction of saxagliptin with andrographolide and their hypoglycemic effect in type 2 diabetes rats." Acta Poloniae Pharmaceutica - Drug Research 80, no. 4 (2023): 667–73. http://dx.doi.org/10.32383/appdr/170911.

Full text
Abstract:
Controlling blood glucose is the primary therapeutic strategy for T2DM. Both saxagliptin and andrographolide possess hypoglycemic effects, which makes the combination easy. This study aimed to evaluate the co-administration of saxagliptin and andrographolide in rats and revealed their combined impact on type 2 diabetes (T2DM). T2DM rat models were established by high-fat diet and the injection of nicotinamide and streptozotocin. The blood glucose and insulin resistance index were monitored after modeling. The pharmacokinetics of saxagliptin was assessed by orally administrating 10 mg/kg saxagl
APA, Harvard, Vancouver, ISO, and other styles
5

Dhillon, Sohita, and Juliane Weber. "Saxagliptin." Drugs 69, no. 15 (2009): 2103–14. http://dx.doi.org/10.2165/11201170-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yang, Lily P. H. "Saxagliptin." Drugs 72, no. 2 (2012): 229–48. http://dx.doi.org/10.2165/11208160-000000000-00000.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lam, Sum, and Maha Saad. "Saxagliptin." Cardiology in Review 18, no. 4 (2010): 213–17. http://dx.doi.org/10.1097/crd.0b013e3181daad5f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Cole, P., N. Serradell, J. Bolos, and R. Castañer. "Saxagliptin." Drugs of the Future 33, no. 7 (2008): 577. http://dx.doi.org/10.1358/dof.2008.033.07.1229229.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gurav, Sachin B., and Neela M. Bhatia. "Assessment of Structural Compatibility of Saxagliptin in Physical Mixtures with some excipient by Using HPLC." Current Pharmaceutical Analysis 16, no. 8 (2020): 1074–82. http://dx.doi.org/10.2174/1573412915666190617153004.

Full text
Abstract:
Introduction: Saxagliptin hydrochloride is an oral hypoglycemic agent used for the treatment of type 2 diabetes mellitus. Saxagliptin is unstable because it undergoes an intra-molecular cyclisation reaction to form a cyclicamidine in both solution and solid states. In pharmaceutical development of saxagliptin it is important to select the excipients which are compatible and help to minimize the formation of cyclicamidine. In excipient compatibility study for saxagliptin it is essential to identify the formation of cyclicamidine and other related substances. Materials and Methods: In the curren
APA, Harvard, Vancouver, ISO, and other styles
10

Dayyih, Wael Abu, Lina Tamimi, Eyad Mallah, Kenza Mansour, Tawfiq Arafat, and Mona Bustami. "SAXAGLIPTIN LEVELS AND ITS PHARMACOKINETIC APPLICATION IN PRESENCE OF SUCRALOSE IN ANIMALS SERUM BY HPLC METHOD: A RESEARCH ARTICLE." International Journal of Pharmacy and Pharmaceutical Sciences 10, no. 2 (2018): 178. http://dx.doi.org/10.22159/ijpps.2015v7i9.6109.

Full text
Abstract:
Objective: It is to develop a simple, valid and rapid chromatographic method for quantification of saxagliptin in rats serum in order to study saxagliptin pharmacokinetic parameters in sucralose fed rats simultaneously to detect any interaction possibility between saxagliptin and sucralose in rats. Methods: In our developed method of analysis, mobile phase consisted of phosphate buffer (pH =4) and methanol (70:30) v/v at flow rate of 1 ml/min with UV detection at 230 nm., C8 column of separation was used with temperature of 40 C ° using injection volume of 50 µl, samples run time was 10 min, a
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Saxagliptin"

1

Rezki, Amel. "Le petit déjeuner standardisé. Un outil diagnostique du statut glycémique et des modifications cardiovasculaires postprandiales ? : Comparaison vs la charge en glucose ; et explorations cardiovasculaires sous saxagliptine vs placebo chez des patients intolérants au glucose." Thesis, Sorbonne Paris Cité, 2019. http://www.theses.fr/2019USPCD029.

Full text
Abstract:
Les phénomènes métaboliques postprandiaux sont primordiaux à la fois pour caractériser le statut glycémique (normal, prédiabète ou diabète, diagnostiqués au mieux par la charge orale de 75g en glucose (HGPO)) mais aussi en raison de modifications cardiovasculaires induites par la prise alimentaire. Un petit-déjeuner standardisé comprenant 75g de glucides (PDJ) pourrait être une alternative. Les holters glycémiques nous ont permis de montrer une grande concordance de l'amplitude/cinétique de la réponse métabolique (glycémies, index d’insulinorésistance, variabilité glycémique) à l’HGPO vs PDJ c
APA, Harvard, Vancouver, ISO, and other styles
2

Gerfer, Stephen [Verfasser], Maria [Gutachter] Grandoch, and Norbert [Gutachter] Gerdes. "Einfluss der Dipeptidylpeptidase-4-Inhibitoren Saxagliptin und Sitagliptin auf die Entwicklung und zelluläre Komposition atherosklerotischer Plaques im Mausmodell der diätinduzierten Insulinresistenz / Stephen Gerfer ; Gutachter: Maria Grandoch, Norbert Gerdes." Düsseldorf : Universitäts- und Landesbibliothek der Heinrich-Heine-Universität Düsseldorf, 2020. http://d-nb.info/1204634742/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zilli, Renato Wilberto. "Eficácia em longo prazo das gliflozinas versus gliptinas no tratamento do diabetes mellitus tipo 2 após falência da metformina como monoterapia: revisão sistemática e metanálise em rede." Universidade de São Paulo, 2017. http://www.teses.usp.br/teses/disponiveis/5/5164/tde-16112017-084026/.

Full text
Abstract:
A metformina é a droga de escolha no tratamento inicial do diabetes mellitus tipo 2 (DM2). Não existe consenso na literatura sobre qual seria a segunda melhor opção terapêutica após a falência desta em longo prazo. Objetivo: avaliar a eficácia em longo prazo de gliflozinas e gliptinas após a falência do tratamento primário com metformina no DM2. Material e métodos: foi realizada uma revisão sistemática para o maior tempo de tratamento nas bases de dados bases Embase, Pubmed (via Medline), Lilacs e Cochrane Library e metanálise em rede com as sulfoniluréias (glimepirida e glipizida) como meta c
APA, Harvard, Vancouver, ISO, and other styles
4

Turnes, Joelle de Melo. "Ineficácia da saxagliptina como droga neuroprotetora em ratos lesados pela 6-OHDA." reponame:Repositório Institucional da UFPR, 2016. http://hdl.handle.net/1884/46136.

Full text
Abstract:
Orientador : Profª. Drª. Maria A. B. F. Vital<br>Dissertação (mestrado) - Universidade Federal do Paraná, Setor de Ciências Biológicas, Programa de Pós-Graduação em Farmacologia. Defesa: Curitiba, 30/11/2016<br>Inclui referências : f. 42-48<br>Área de concentração<br>Resumo: Existe um interesse crescente na investigação de um fármaco hipoglicêmico para o tratamento da Doença de Parkinson (DP), uma vez que foram verificados mecanismos em comum entre DP e Diabetes Mellitus (DM) e vários desses compostos mostraram potenciais efeitos neuroprotetores, dentre eles a classe dos inibidores dipeptidil
APA, Harvard, Vancouver, ISO, and other styles
5

Wang, ZI-Chen, and 王子誠. "The risk of cardio-cerebral vascular events in type 2 diabetes patients with the usage of saxagliptin." Thesis, 2016. http://ndltd.ncl.edu.tw/handle/40391727183387177674.

Full text
Abstract:
碩士<br>高雄醫學大學<br>藥學系碩士在職專班<br>104<br>Background: Saxagliptin is an oral hypoglycemic agent that can control blood sugar by inhibiting the metabolism of incretin. Several research studies recently showed that saxagliptin may increase the risk of cardiovascular events recetently. The aims of our study were to evaluate the risk of cardio-cerebral vascular events in patients who received saxagliptin and explore the precipitating risk factors of cardio-cerebral vascular events. Methods: There were two parts in our study. First, a systemic review and meta-analysis of randomized controlled studies of
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Saxagliptin"

1

Blokdijk, G. J. Saxagliptin Hydrochloride; A Clear and Concise Reference. CreateSpace Independent Publishing Platform, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Saxagliptin"

1

Deerberg, Joerg. "Process Safety in the Large-Scale Manufacture of an Adamantane α-Ketoacid Precursor of Saxagliptin." In ACS Symposium Series. American Chemical Society, 2014. http://dx.doi.org/10.1021/bk-2014-1181.ch006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

"Saxagliptin." In Checkliste Arzneimittel A–Z, edited by Detlev Schneider and Frank Richling. Georg Thieme Verlag, 2013. http://dx.doi.org/10.1055/b-0034-82749.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

"Saxagliptin." In PharmacotherapyFirst Drug Information. The American Pharmacists Association, 2017. http://dx.doi.org/10.21019/druginformation.saxagliptin.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Saxagliptin (r)." In Drugs Handbook 2012–2013. Bloomsbury Academic, 2011. http://dx.doi.org/10.5040/9781350363595.art-1548.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Mason, PR, R. Kubant, AM Jacoby, et al. "Saxagliptin Treatment Reduces sCD40 Levels and Increases Endothelial Nitric Oxide Bioavailability in Obese, Insulin-Resistant Rats." In The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego. Endocrine Society, 2010. http://dx.doi.org/10.1210/endo-meetings.2010.part1.p10.p1-487.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Faruk Khan, M. O. "Diabetes and Antidiabetic Drugs." In Medicinal Chemistry for Pharmacy Students. BENTHAM SCIENCE PUBLISHERS, 2024. http://dx.doi.org/10.2174/9789815179729124030009.

Full text
Abstract:
This chapter is a comprehensive account of diabetes and the medicinal chemistry of antidiabetic drugs. It provides the mechanism of disease progression and drug action and detailed structure-activity relationships (SAR) of antidiabetic drugs to give the knowledge base for pharmacists. After studying this chapter, students will be able to: • Discuss the epidemiology and etiology of diabetes. • Describe the clinical features of diabetes and differentiate between type I and type II diabetes. • Discuss various risk factors and corresponding mechanisms responsible for the development of diabetes. R
APA, Harvard, Vancouver, ISO, and other styles
7

Afolabi, Saheed Olanrewaju, Joy Folahan, Olalekan Agede, and Olufunke Olorundare. "Combined Intranasal Insulin/Saxagliptin/Metformin Therapies Ameliorates the Effect of Combined Oral Contraceptives (Cos)-Induced Metabolic Syndrome (MetS) with a Major Target on Glucose Metabolism in Adult Female Wistar Rats: A Recent Study." In New Horizons in Medicine and Medical Research Vol. 12. Book Publisher International (a part of SCIENCEDOMAIN International), 2022. http://dx.doi.org/10.9734/bpi/nhmmr/v12/6111f.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Saxagliptin"

1

Del Prato, S., E. Johnsson, R. Garcia-Sanchez, et al. "Regulierung von Dapagliflozin-assoziierten Genitalinfektionen durch Saxagliptin: eine gepoolte Verträglichkeitsanalyse." In Diabetes Kongress 2019 – 54. Jahrestagung der DDG. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1688348.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Simonson, D., T. Vilsboll, E. Ekholm, et al. "Glykämische Variabilitätsprofile durch kontinuierliches Glukosemonitoring sind bei Typ-2-Diabetes für Dapagliflozin plus Saxagliptin von größerem Nutzen im Vergleich zu Insulin glargin." In Diabetes Kongress 2019 – 54. Jahrestagung der DDG. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1688347.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Saxagliptin' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography